

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/029842 A3

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 29/00 (2006.01)
C07D 405/04 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2024/040259

(22) International Filing Date:

31 July 2024 (31.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/530,142 01 August 2023 (01.08.2023) US
23196351.3 08 September 2023 (08.09.2023) EP

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **COMTE, Myriam**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **CRUCIANI, Paul**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **LARQUETOUX, Laurent**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **LATREMOLIERE, Olivier**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **LEMAITRE, Clement**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **OCHSENBEIN, Philippe**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **VERSPROUMY, Pierre**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

(74) Agent: **HERZFELD, Deborah** et al.; McNeill PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

13 March 2025 (13.03.2025)

(54) Title: PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-L-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-L-YL]-PENT-2-ENENTRILE AND SOLVATE FORMS THEREOF

(57) Abstract: Disclosed herein are novel methods for preparing 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enitrile, including various solvate forms and intermediates thereof. Also disclosed herein are novel solvate forms and intermediates of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enitrile.



WO 2025/029842 A3